Papadimitriou Lampros, Hamo Carine E, Butler Javed
From the Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
From the Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
Trends Cardiovasc Med. 2017 Jul;27(5):316-323. doi: 10.1016/j.tcm.2017.01.003. Epub 2017 Jan 11.
Heart Failure is a global epidemic, affecting approximately 5 million adults in the U.S.A. The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomic systems. The 2016 focused pharmacologic update on the current Heart Failure Guidelines introduces the use of two newly approved regimens valsartan/sacubitril and ivabradine. Over the last two decades, guideline directed medical therapy has accomplished significant improvement in survival rates among heart failure patients; however these novel compounds were reported to exert additional mortality and morbidity benefits, in heart failure subpopulations with reduced ejection fraction.
心力衰竭是一种全球性疾病，在美国约有500万成年人受其影响。当代药物治疗的基石是针对过度激活的肾素 - 血管紧张素 - 醛固酮系统和交感自主神经系统。2016年《心力衰竭指南》重点药物更新引入了两种新批准的治疗方案——缬沙坦/沙库巴曲和伊伐布雷定。在过去二十年中，指南指导的药物治疗已使心力衰竭患者的生存率有了显著提高；然而，据报道，这些新型化合物在射血分数降低的心力衰竭亚组人群中具有额外的降低死亡率和发病率的益处。
